Yext CEO Drops $9/Share Buyout Plan, Company to Repurchase $150M in Stock
Yext CEO Michael Walrath withdraws his $9-per-share acquisition proposal due to financing challenges, while the company announces a $150 million stock buyback program.
NOTRELOAD AI
Wells Fargo Gives Rapport Therapeutics an “Overweight” Rating
Wells Fargo analyst rates Rapport Therapeutics as Overweight with $43 target, citing strong Phase 2a seizure data and promising efficacy.
Morgan Stanley Cuts Humana Rating Amid Medicare Advantage Concerns
Morgan Stanley downgraded Humana to Underweight, citing policy risks and disappointing Medicare Advantage updates, with a new price target of $174.
Hain Celestial Sells Snacks Business for $115M to Focus on Core Brands
Hain Celestial sells North American snacks unit including Terra chips to Canadian manufacturer for $115M, streamlining portfolio to boost margins and reduce debt.
MoonLake's Sonelokimab Gets FDA Fast Track for Rare Skin Disease
MoonLake Immunotherapeutics receives FDA Fast Track designation for sonelokimab in palmoplantar pustulosis, accelerating development for this untreated skin condition.
Trump Launches $12B Strategic Minerals Stockpile to Counter China
President Trump unveils Project Vault, a $12 billion initiative to stockpile critical minerals, reducing US dependence on China and protecting manufacturers from supply disruptions.